Use of strontium salt for the treatment and/or prophylaxis of Paget's disease, osteoporosis, hyperparathyroidism and rheumatoid arthritis

Christian Hansen; Henrik Nilsson; Jens Enevold Thaulov Andersen; Stephan Christgau; J. Andersen; E. Andersen

Use of strontium salt for the treatment and/or prophylaxis of Paget's disease, osteoporosis, hyperparathyroidism and rheumatoid arthritis

Christian Hansen (Inventor), Henrik Nilsson (Inventor), Jens Enevold Thaulov Andersen (Inventor), Stephan Christgau (Inventor), J. Andersen (Inventor), E. Andersen (Inventor)

Research output: Patent

Abstract

NOVELTY - Use of a strontium salt (I) (having a water-solubility at room temperature at about 1-100 g/l) in medicine. USE - (I) is useful for the preparation of a pharmaceutical composition for the treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, e.g. a human female or male adult, adolescent or a child, such as, e.g., osteoporosis, osteoarthritis, osteoporosis, osteopenia and Paget's disease, hypercalcemia of malignancy, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, osteodystrophy, myositis ossificans, Bechterew's disease, malignant hypercalcemia, osteolytic lesions produced by bone metastasis, bone pain due to bone metastasis, bone loss due to sex steroid hormone deficiency, bone abnormalities due to steroid hormone treatment, bone abnormalities caused by cancer therapeutics, osteomalacia, Bechet's disease, hyperostosis, metastatic bone disease, immobilization induced osteopenia, osteoporosis or glucocorticoid-induced osteopenia or osteoporosis, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, for the improvement of fracture healing after traumatic or a traumatic fracture, and for the maintenance or increase of energy level, for building up or strengthening muscle tissues and for weight gain (all claimed). ADVANTAGE - (I) has improved bioavailability, absorption and reduced side effects and reduced daily dosage. The bioavailability of (I) was tested in Wilsar rats. The results showed that there was a rapid and highly significant increase in serum strontium concentrations of (I). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a strontium salt (I) having a water-solubility at room temperature at about 1-100 g/l; provided that the salt is not strontium L-aspartate trihydrate or strontium L-glutamate hexahydrate; (2) preparations of (I); and (3) a pharmaceutical composition comprising (I) together with one or more excipients.

Original language	English
Patent number	WO2004098619-A2
Country/Territory	International Bureau of the World Intellectual Property Organization (WIPO)
Publication status	Published - 2004
Externally published	Yes

Bibliographical note

Patent:
No.: EP1534305-A2

Patent:
Country: Australia
No.: AU2004237439-A1

Patent:
Country: United States
No.: US2006122274-A1

Patent:
No.: EP1534305-B1

Patent:
No.: JP2006525243-W

Patent:
Country: Germany
No.: DE602004002832-E

Patent:
No.: EP1745791-A2

Patent:
No.: EP1534305-B9

Patent:
Country: Germany
No.: DE602004002832-T2

Patent:
No.: ES2275218-T3

Patent:
Country: United States
No.: US7595342-B2

Patent:
No.: JP4354984-B2

Patent:
Country: United States
No.: US2010048697-A1

Patent:
No.: EP2266585-A2

Patent:
No.: EP1745791-A3

Patent:
No.: EP2266585-A3

OpenUrl availability

Full text

Cite this

@misc{452134d29df347fdbe54a4bbc05d4f6e,

title = "Use of strontium salt for the treatment and/or prophylaxis of Paget's disease, osteoporosis, hyperparathyroidism and rheumatoid arthritis",

abstract = "NOVELTY - Use of a strontium salt (I) (having a water-solubility at room temperature at about 1-100 g/l) in medicine. USE - (I) is useful for the preparation of a pharmaceutical composition for the treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, e.g. a human female or male adult, adolescent or a child, such as, e.g., osteoporosis, osteoarthritis, osteoporosis, osteopenia and Paget's disease, hypercalcemia of malignancy, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, osteodystrophy, myositis ossificans, Bechterew's disease, malignant hypercalcemia, osteolytic lesions produced by bone metastasis, bone pain due to bone metastasis, bone loss due to sex steroid hormone deficiency, bone abnormalities due to steroid hormone treatment, bone abnormalities caused by cancer therapeutics, osteomalacia, Bechet's disease, hyperostosis, metastatic bone disease, immobilization induced osteopenia, osteoporosis or glucocorticoid-induced osteopenia or osteoporosis, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, for the improvement of fracture healing after traumatic or a traumatic fracture, and for the maintenance or increase of energy level, for building up or strengthening muscle tissues and for weight gain (all claimed). ADVANTAGE - (I) has improved bioavailability, absorption and reduced side effects and reduced daily dosage. The bioavailability of (I) was tested in Wilsar rats. The results showed that there was a rapid and highly significant increase in serum strontium concentrations of (I). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a strontium salt (I) having a water-solubility at room temperature at about 1-100 g/l; provided that the salt is not strontium L-aspartate trihydrate or strontium L-glutamate hexahydrate; (2) preparations of (I); and (3) a pharmaceutical composition comprising (I) together with one or more excipients.",

author = "Christian Hansen and Henrik Nilsson and Andersen, {Jens Enevold Thaulov} and Stephan Christgau and J. Andersen and E. Andersen",

note = "Patent: No.: EP1534305-A2 Patent: Country: Australia No.: AU2004237439-A1 Patent: Country: United States No.: US2006122274-A1 Patent: No.: EP1534305-B1 Patent: No.: JP2006525243-W Patent: Country: Germany No.: DE602004002832-E Patent: No.: EP1745791-A2 Patent: No.: EP1534305-B9 Patent: Country: Germany No.: DE602004002832-T2 Patent: No.: ES2275218-T3 Patent: Country: United States No.: US7595342-B2 Patent: No.: JP4354984-B2 Patent: Country: United States No.: US2010048697-A1 Patent: No.: EP2266585-A2 Patent: No.: EP1745791-A3 Patent: No.: EP2266585-A3 ; WO2004098619-A2",

year = "2004",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Use of strontium salt for the treatment and/or prophylaxis of Paget's disease, osteoporosis, hyperparathyroidism and rheumatoid arthritis

AU - Hansen, Christian

AU - Nilsson, Henrik

AU - Andersen, Jens Enevold Thaulov

AU - Christgau, Stephan

AU - Andersen, J.

AU - Andersen, E.

N1 - Patent: No.: EP1534305-A2 Patent: Country: Australia No.: AU2004237439-A1 Patent: Country: United States No.: US2006122274-A1 Patent: No.: EP1534305-B1 Patent: No.: JP2006525243-W Patent: Country: Germany No.: DE602004002832-E Patent: No.: EP1745791-A2 Patent: No.: EP1534305-B9 Patent: Country: Germany No.: DE602004002832-T2 Patent: No.: ES2275218-T3 Patent: Country: United States No.: US7595342-B2 Patent: No.: JP4354984-B2 Patent: Country: United States No.: US2010048697-A1 Patent: No.: EP2266585-A2 Patent: No.: EP1745791-A3 Patent: No.: EP2266585-A3

PY - 2004

Y1 - 2004

N2 - NOVELTY - Use of a strontium salt (I) (having a water-solubility at room temperature at about 1-100 g/l) in medicine. USE - (I) is useful for the preparation of a pharmaceutical composition for the treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, e.g. a human female or male adult, adolescent or a child, such as, e.g., osteoporosis, osteoarthritis, osteoporosis, osteopenia and Paget's disease, hypercalcemia of malignancy, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, osteodystrophy, myositis ossificans, Bechterew's disease, malignant hypercalcemia, osteolytic lesions produced by bone metastasis, bone pain due to bone metastasis, bone loss due to sex steroid hormone deficiency, bone abnormalities due to steroid hormone treatment, bone abnormalities caused by cancer therapeutics, osteomalacia, Bechet's disease, hyperostosis, metastatic bone disease, immobilization induced osteopenia, osteoporosis or glucocorticoid-induced osteopenia or osteoporosis, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, for the improvement of fracture healing after traumatic or a traumatic fracture, and for the maintenance or increase of energy level, for building up or strengthening muscle tissues and for weight gain (all claimed). ADVANTAGE - (I) has improved bioavailability, absorption and reduced side effects and reduced daily dosage. The bioavailability of (I) was tested in Wilsar rats. The results showed that there was a rapid and highly significant increase in serum strontium concentrations of (I). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a strontium salt (I) having a water-solubility at room temperature at about 1-100 g/l; provided that the salt is not strontium L-aspartate trihydrate or strontium L-glutamate hexahydrate; (2) preparations of (I); and (3) a pharmaceutical composition comprising (I) together with one or more excipients.

AB - NOVELTY - Use of a strontium salt (I) (having a water-solubility at room temperature at about 1-100 g/l) in medicine. USE - (I) is useful for the preparation of a pharmaceutical composition for the treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, e.g. a human female or male adult, adolescent or a child, such as, e.g., osteoporosis, osteoarthritis, osteoporosis, osteopenia and Paget's disease, hypercalcemia of malignancy, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, osteodystrophy, myositis ossificans, Bechterew's disease, malignant hypercalcemia, osteolytic lesions produced by bone metastasis, bone pain due to bone metastasis, bone loss due to sex steroid hormone deficiency, bone abnormalities due to steroid hormone treatment, bone abnormalities caused by cancer therapeutics, osteomalacia, Bechet's disease, hyperostosis, metastatic bone disease, immobilization induced osteopenia, osteoporosis or glucocorticoid-induced osteopenia or osteoporosis, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, for the improvement of fracture healing after traumatic or a traumatic fracture, and for the maintenance or increase of energy level, for building up or strengthening muscle tissues and for weight gain (all claimed). ADVANTAGE - (I) has improved bioavailability, absorption and reduced side effects and reduced daily dosage. The bioavailability of (I) was tested in Wilsar rats. The results showed that there was a rapid and highly significant increase in serum strontium concentrations of (I). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a strontium salt (I) having a water-solubility at room temperature at about 1-100 g/l; provided that the salt is not strontium L-aspartate trihydrate or strontium L-glutamate hexahydrate; (2) preparations of (I); and (3) a pharmaceutical composition comprising (I) together with one or more excipients.

M3 - Patent

M1 - WO2004098619-A2

ER -